影像引导高剂量率近距离放疗作为医学上无法手术的早期子宫内膜癌患者的首选方法
中位随访67个月,3年和5年总生存率分别为69%和55%,仅观察到G1阴道顶端狭窄,结论认为该方案在肥胖和老年患者中可行且安全。
要点
- 中位随访67个月,3年和5年总生存率分别为69%和55%。
核心结论
- CT引导HDR-ICBT是肥胖和老年FIGO I期子宫内膜癌患者可行且安全的管理方式。
- 治疗组的生存结局更多受相关合并症影响而非子宫内膜癌进展影响。
研究设计与样本
- 前瞻性研究,纳入78例因医学合并症(包括病态肥胖或年龄相关衰弱综合征)无法手术的FIGO I-II期子宫内膜癌患者。
- 所有分次均使用计算机断层扫描(CT)计划。
主要发现
- BMI≥40对总生存(OS)或无进展生存(PFS)无统计学显著影响。
- 全人群3年和5年OS分别为69%和55%。
关键数值与推荐
- 仅观察到G1阴道顶端狭窄。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: About 3-9% of patients with endometrial cancer are unable to undergo surgery due to medical comorbidities, including morbid obesity, or age-related frailty syndrome. An alternative curative option is irradiation. The aim of this prospective study was to evaluate clinical outcomes of high-dose-rate intracavitary brachytherapy (HDR-ICBT) treatment in such patients. MATERIALS AND METHODS: Seventy-eight patients with FIGO stage I-II endometrial cancer disqualified from surgery were treated with HDR-ICBT with 45-52,5 Gy prescribed to high-risk clinical target volume (HR-CTV) in 5-9 fractions given once a week. All fractions were planned using computed tomography (CT) scans. RESULTS: The median follow-up time was 67 months. Median age was 79 years (range: 42-93 years). Median body mass index (BMI) was 39,1 kg/m2 (range: 24,2-68 kg/m2). We observed no statistically significant impact of BMI ≥ 40 on overall survival (OS) or prgression free survival (PFS). The 3- and 5-year OS for the whole population were 69% and 55%, respectively. The impact of high risk features (FIGO II, grade 3 or type 2 cancer) on OS was significant (p = 0,049). The 5-year cumulative incidence of local failure, distant metastases and non-cancer death were 12,9% [95% CI: 5,4%-20,5%], 6,4% [95% CI: 0,9%-11,9%], 33,1% [95% CI: 22,3%-43,9%], respectively. The 5-year risk of cancer and non-cancer death were 9% (95% CI: 3%-16%) and 36% (95% CI: 25%-47%), respectively. We observed G1 vaginal apex stenosis only. CONCLUSIONS: CT-guided HDR-ICBT is a feasible and safe management of FIGO stage I endometrial cancer in obese and elderly patients. The survival outcome of the treated group is influenced more by associated comorbidities than by the progression of endometrial cancer.
引用
- Rydzinski M, Bijok M, Michalski W, et al. Image-guided high-dose-rate brachytherapy as the method of choice in medically inoperable early-stage endometrial cancer patients. Gynecol Oncol. 2023. PMID: 38035868. doi:10.1016/j.ygyno.2023.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。